Tata Chemicals Ltd (TATACHEM)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Standalone Q2 FY27 revenue 1,303 Cr +8% y-y; EBITDA 292 Cr +22% y-y; PAT 122 Cr -31% y-y
- Consolidated Q2 FY27 revenue 4,177 Cr +8% y-y; EBITDA 381 Cr down from 537 Cr; loss after tax 50 Cr
- Global soda ash market challenged by oversupply, especially from China; India demand remains healthy
- Kenya operations suspended; legal and administrative processes ongoing with commitment to resume
- US business acquired Searles Valley contracts for 2 years; logistics proximity expected to improve margins
- UK operations impacted by high energy and logistics costs; outlook tied to cost moderation
- Capex budget ~1,000 Cr for FY27 and FY28 including growth projects
- Focus on operational excellence, cost management, and capital discipline amid geopolitical and market uncertainties
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 TATACHEM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add TATACHEM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Tata Chemicals Ltd
Important.
The summary above is generated automatically from Tata Chemicals Ltd's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.